Thursday, 30. March 2017

PARI Pharma development featuring eFlow Technology for Bronchiolitis Obliterans Syndrome (BOS) is licensed to Breath Therapeutics.

PARI Pharma has licensed its first-in-class inhalation development program for Bronchiolitis Obliterans Syndrome (BOS) to Breath Therapeutics GmbH...
Wednesday, 02. November 2016

Sunovion Announces FDA Filing Acceptance of New Drug Application for Sun-101/eFlow® for the Treatment of Patients with Chronic Obstuctive Pulmonary Disease (COPD)

- Sun-101/eflow® (glycopyrrolate) NDA is currently under review; if approved, it would represent the first available nebulized long-acting muscarinic...
Sunovion Submits New Drug Application
Monday, 01. August 2016

Sunovion Submits New Drug Application for SUN-101/eFlow® to the FDA

For the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)
Monday, 01. August 2016

Sunovion Announces Results of Phase 3 Long-Term Safety Study

Showing SUN-101/eFlow®(glycopyrrolate) Was Well-Tolerated in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Friday, 15. April 2016

Raptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled Levofloxacin

Granted for Three Distinct Indications: Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis and in Patients...